RCWM
TSHA icon

Royal Capital Wealth Management’s Taysha Gene Therapies TSHA Stock Holding History

Royal Capital Wealth Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,665
Closed -$18.9K – 98
2023
Q4 		$18.9K Buy
+10,665
New +$21.3K 0.02% 92

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Royal Capital Wealth Management's TSHA Position: Q1 2024 in Review

Royal Capital Wealth Management sold out of Taysha Gene Therapies (TSHA) in Q1 2024, closing a stake of 10,665 shares — an estimated $18.9K sold.

Royal Capital Wealth Management first reported a position in TSHA in Q4 2023 and held it in 1 quarter. The position peaked at $18.9K in Q4 2023. 109 funds tracked by Wall St. Rank hold TSHA as of Q1 2024.

  • Royal Capital Wealth Management reported no remaining Taysha Gene Therapies position as of Q1 2024 after selling out during the quarter.
  • Royal Capital Wealth Management sold 10,665 Taysha Gene Therapies shares in Q1 2024, an estimated $18.9K.
  • Royal Capital Wealth Management first reported a position in Taysha Gene Therapies in Q4 2023 and held it in 1 quarter.
  • Royal Capital Wealth Management's Taysha Gene Therapies position peaked at $18.9K in Q4 2023.
  • 109 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2024.

Based on Royal Capital Wealth Management's 13F filing for Q1 2024, filed 15 May 2024.